Elekta (EKTAY) Stock Price, News & Analysis

Company Overview

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Key Stats

• Today's Range: $5.00 to $5.22
• 50-Day Range: $4.85 to $5.49
• 52-Week Range: $4.36 to $7.13
• Volume: 1,290 shs
• Average Volume: 7,226 shs
• Market Capitalization: $1.92 billion
• P/E Ratio: 100.02
• Dividend Yield: 2.40%
• Price Target: N/A
• Consensus Rating: Hold

Elekta Stock Analysis - MarketRank™

Elekta scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Elekta.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 19.44%

Earnings Growth

Earnings for Elekta are expected to grow by 19.44% in the coming year, from $0.36 to $0.43 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Elekta is 100.02, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.87.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elekta is 100.02, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.25.

Price to Book Value per Share Ratio

Elekta has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Elekta has been sold short.

Short Interest Ratio / Days to Cover

Elekta has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elekta has recently decreased by 99.51%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Elekta pays a meaningful dividend of 2.34%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Elekta does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Elekta is 240.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Elekta will have a dividend payout ratio of 27.91% next year. This indicates that Elekta will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the float of Elekta has been sold short.

Short Interest Ratio / Days to Cover

Elekta has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elekta has recently decreased by 99.51%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.61

News Sentiment

Elekta has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Elekta this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elekta insiders have not sold or bought any company stock.

Percentage Held by Insiders

41.28% of the stock of Elekta is held by insiders. A high percentage of insider ownership can be a sign of company health.

EKTAY Stock Analysis - Frequently Asked Questions

How have EKTAY shares performed this year?

Elekta's stock was trading at $5.66 on January 1st, 2025. Since then, EKTAY stock has decreased by 11.7% and is now trading at $5.00.
View the best growth stocks for 2025 here.

How were Elekta's earnings last quarter?

Elekta AB (OTCMKTS:EKTAY) issued its quarterly earnings results on Wednesday, May, 28th. The company reported $0.11 EPS for the quarter, missing analysts' consensus estimates of $0.13 by $0.02. The business had revenue of $503.22 million for the quarter, compared to the consensus estimate of $507.19 million. Elekta had a net margin of 1.15% and a trailing twelve-month return on equity of 11.55%.

How do I buy shares of Elekta?

Shares of EKTAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/28/2025
• Today: 7/01/2025
• Next Earnings (Estimated): 8/27/2025
• Fiscal Year End: 4/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:EKTAY
• CIK: 1451160
• Web: www.elekta.com
• Phone: (685) 872-5400
• Fax: 46-8-587-255-00
• Employees: 4,718
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.05
• Trailing P/E Ratio: 17.50
• Forward P/E Ratio: 13.89
• P/E Growth: N/A
• Net Income: $22.37 million
• Net Margins: 1.15%
• Pretax Margin: 2.72%
• Return on Equity: 11.55%
• Return on Assets: 3.75%

Debt

• Debt-to-Equity Ratio: 0.70
• Current Ratio: 1.09
• Quick Ratio: 0.86

Sales & Book Value

• Annual Sales: $1.71 billion
• Price / Sales: 1.12
• Cash Flow: $0.60 per share
• Price / Cash Flow: 8.29
• Book Value: $2.19 per share
• Price / Book: 2.28

Miscellaneous

• Outstanding Shares: 383,570,000
• Free Float: 225,231,000
• Market Cap: $1.92 billion
• Optionable: Not Optionable
• Beta: 1.20